comparemela.com

Page 4 - Crick Avenue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K -December 14, 2023 at 10:24 am EST

a7197w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesAnna manzAdrian kempInvestor relations teamSecurities exchangeEuropean union withdrawalCompany on twitter astrazenecaCommission file numberPurchase of astrazenecaForeign issuerSecurities exchange actFile numberCrick avenueRegulationst rulePerson discharging managerial responsibilities

AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST

a4665w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesNew yorkUniversity of washingtonUnited kingdomAdam simpsonIskra reicAdrian kempInvestor relations teamRegulatory news serviceCompany secretaryCommission file numberIcosavax incHoldings incDrug administrationIsochrone merger sub incSecurities exchange

AstraZeneca : Update on CRYSTALIZE evidence trials - Form 6-K -December 01, 2023 at 06:29 am EST

a2725v FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesUnited kingdomSharon barrColl cardiolAdrian kempSecurities exchangeEuropean medicines agency lokelmaCompany secretaryAstrazeneca pharmaceuticalsInvestor relations teamDiabetes work groupCommission file numberForeign issuerSecurities exchange actFile numberCrick avenue

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K -November 24, 2023 at 07:16 am EST

a5089u FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesAdrian kempMichel demarPurchase of astrazenecaEuropean union withdrawalCompany secretarySecurities exchangeCommission file numberInvestor relations teamCompany on twitter astrazenecaForeign issuerSecurities exchange actFile numberCrick avenueRegulationst rule

AstraZeneca : Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer - Form 6-K -November 17, 2023 at 06:39 am EST

a8163t FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesUnited kingdomAstrazeneca truqapCommission file numberDrug administrationSecurities exchangeForeign issuerSecurities exchange actFile numberCrick avenueRegulationst ruleNew england journal

vimarsana © 2020. All Rights Reserved.